225 related articles for article (PubMed ID: 26911377)
1. AI-related BMD variation in actual practice conditions: A prospective cohort study.
Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Garcia-Giralt N; Garrigos L; Rodriguez-Morera J; Albanell J; Martínez-García M; González I; Diez-Perez A; Tusquets I; Nogués X
Endocr Relat Cancer; 2016 Apr; 23(4):303-12. PubMed ID: 26911377
[TBL] [Abstract][Full Text] [Related]
2. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
María RS; Marta PM; Sonia S; Natalia GG; Tamara M; Ignasi T; Maria MG; Jaime RM; Adolfo DP; Joan A; Xavier N
Bone; 2016 Nov; 92():1-8. PubMed ID: 27519968
[TBL] [Abstract][Full Text] [Related]
3. Bone health evaluation one year after aromatase inhibitors completion.
Pineda-Moncusí M; Servitja S; Casamayor G; Cos ML; Rial A; Rodriguez-Morera J; Tusquets I; Diez-Perez A; Garcia-Giralt N; Nogués X
Bone; 2018 Dec; 117():54-59. PubMed ID: 30223134
[TBL] [Abstract][Full Text] [Related]
4. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates may protect against bone loss in postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor therapy: results from a meta-analysis.
Su G; Xiang Y; He G; Jiang C; Li C; Yan Z; Zhong Y
Arch Med Res; 2014 Oct; 45(7):570-9. PubMed ID: 25450582
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of exemestane therapy on bone mineral density supported by bisphosphonates: Results of 5-year adjuvant treatment in postmenopausal women with early-stage breast cancer.
Hirano A; Inoue H; Ogura K; Hattori A; Yukawa H; Sakaguchi S; Matsuoka A; Tanaka N; Kodera A; Kamimura M; Naritaka Y; Shimizu T
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e238-e242. PubMed ID: 29932305
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitors attenuate the effect of alendronate in women with breast cancer.
Kong SH; Kim JH; Kim SW; Shin CS
J Bone Miner Metab; 2020 Sep; 38(5):730-736. PubMed ID: 32405760
[TBL] [Abstract][Full Text] [Related]
9. Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons.
Markopoulos C; Koukouras D; Venizelos V; Karyda I; Xepapadakis G; Misitzis J; Kalogerakos K; Poulakaki F; Natsiopoulos J; Zobolas V; Savidou C; Antonopoulou Z; Tzoracoleftherakis E
Breast; 2016 Jun; 27():27-34. PubMed ID: 27212697
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
11. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
12. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
Kwan ML; Yao S; Laurent CA; Roh JM; Quesenberry CP; Kushi LH; Lo JC
Breast Cancer Res Treat; 2018 Apr; 168(2):523-530. PubMed ID: 29249058
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
[TBL] [Abstract][Full Text] [Related]
14. Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy.
Dieckmeyer M; Ruschke S; Rohrmeier A; Syväri J; Einspieler I; Seifert-Klauss V; Schmidmayr M; Metz S; Kirschke JS; Rummeny EJ; Zimmer C; Karampinos DC; Baum T
BMC Musculoskelet Disord; 2019 Nov; 20(1):515. PubMed ID: 31694630
[TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Majithia N; Atherton PJ; Lafky JM; Wagner-Johnston N; Olson J; Dakhil SR; Perez EA; Loprinzi CL; Hines SL
Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334
[TBL] [Abstract][Full Text] [Related]
17. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
Kalder M; Kyvernitakis I; Albert US; Baier-Ebert M; Hadji P
Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
[TBL] [Abstract][Full Text] [Related]
20. Practical guidance for the management of aromatase inhibitor-associated bone loss.
Hadji P; Body JJ; Aapro MS; Brufsky A; Coleman RE; Guise T; Lipton A; Tubiana-Hulin M
Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
